JP2002193795A - Local anesthetic tape - Google Patents

Local anesthetic tape

Info

Publication number
JP2002193795A
JP2002193795A JP2001337251A JP2001337251A JP2002193795A JP 2002193795 A JP2002193795 A JP 2002193795A JP 2001337251 A JP2001337251 A JP 2001337251A JP 2001337251 A JP2001337251 A JP 2001337251A JP 2002193795 A JP2002193795 A JP 2002193795A
Authority
JP
Japan
Prior art keywords
local anesthetic
skin
tape
weight
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001337251A
Other languages
Japanese (ja)
Inventor
Katsunori Nakagawa
勝憲 中川
Takeshi Ishida
猛 石田
Mitsuhiro Sato
光洋 佐藤
Hiromi Koga
裕美 古賀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yutoku Pharmaceutical Industries Co Ltd
Original Assignee
Yutoku Pharmaceutical Industries Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yutoku Pharmaceutical Industries Co Ltd filed Critical Yutoku Pharmaceutical Industries Co Ltd
Priority to JP2001337251A priority Critical patent/JP2002193795A/en
Publication of JP2002193795A publication Critical patent/JP2002193795A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide a local anesthetic tape having a certain level of rigidity to prevent the mutual adhesion of the plasters caused by the bending of the plaster by its own weight in pasting and free from the problems of the increase in production cost and the safety to the skin caused by the use of an unnecessarily large amount of local anesthetic agent, the lowering of the percutaneous absorption caused by the crystallization of the drug in the distribution stage and the lowering of the production efficiency and to facilitate the confirmation of the presence of the tape or the peeling of the tape at the medical treatment site by coloring the substrate in a conspicuous color such as white color. SOLUTION: A plaster containing 5-30 wt.% local anesthetic agent, 10-50 wt.% rubber-based tacky agent, 10-50 wt.% tackifier and 10-50 wt.% liquid paraffin as main components is supported on a substrate and the laminate is made to have moderate followability to the skin and a moderate rigidity to prevent the mutual adhesion of the plasters by the bending of the laminate by its own weight in pasting.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】皮膚表面における注射や水痘
を除去する等の処置の際に、あるいは静脈留置針穿刺
時、硬膜または腰椎または関節穿刺時、皮膚小手術前の
局所麻酔に利用可能で、処置時の疼痛緩和を目的とした
局所麻酔剤を含有するテープ剤であり、特に従来よりも
低い薬物含有量において経皮吸収性に優れ、かつ取扱い
性に優れ、副作用の少ない局所麻酔用テープ剤に関する
ものである。
BACKGROUND OF THE INVENTION The present invention can be used for local anesthesia prior to skin microsurgery, such as during injection on the skin surface or removal of varicella, at the time of puncture of an indwelling needle, dura or lumbar spine or joint puncture. , A tape containing a local anesthetic for the purpose of pain relief during treatment, especially a tape for local anesthesia with excellent percutaneous absorbability and excellent handling properties with less drug content than before, with less side effects It relates to the agent.

【0002】[0002]

【従来の技術】従来、リドカインに代表されるようなア
ミド型局所麻酔剤を含有する皮膚あるいは粘膜に適用す
るための外用製剤が種々検討されており、軟膏剤や液剤
が提案されている。
2. Description of the Related Art Various external preparations containing an amide-type local anesthetic such as lidocaine for application to skin or mucous membranes have been studied, and ointments and liquid preparations have been proposed.

【0003】これらは主として表面麻酔のために使用さ
れているが、アミド型局所麻酔剤の皮膚透過性が低いた
め、十分な薬効を得ることが困難であり、静脈留置針穿
刺時、硬膜または腰椎または関節穿刺時、皮膚小手術前
の局所麻酔等に対しては満足な効果を得るには至ってい
なかった。また、軟膏剤や液剤では、投与の際に手指を
汚したり、投与後に衣服を汚す等の欠点があり、またそ
の結果、投与部位以外の皮膚あるいは粘膜に付着した薬
物が、その部分の感覚を麻痺させてしまう等の不都合が
起きることもあった。
[0003] These are mainly used for surface anesthesia. However, since the skin permeability of the amide-type local anesthetic is low, it is difficult to obtain a sufficient drug effect. At the time of lumbar spine or joint puncture or local anesthesia before skin minor surgery, satisfactory effects have not been obtained. In addition, ointments and liquid preparations have drawbacks such as soiling of fingers during administration and soiling of clothes after administration, and as a result, drugs adhering to skin or mucous membranes other than the administration site may cause sensation in those parts. Inconveniences such as paralysis sometimes occurred.

【0004】また、特開昭60−16916号、特開昭
60−185713号、特開昭63−93714号、特
開平4−208229号、特開平6−145051号等
には、基剤中の薬物濃度を高くし、薬物の結晶を析出さ
せた経皮吸収貼付剤や、基剤に対する飽和溶解度を超え
て薬物を過飽和状態で存在させた経皮吸収貼付剤が開示
されている。
Further, JP-A-60-16916, JP-A-60-185713, JP-A-63-93714, JP-A-4-208229, JP-A-6-145051, etc. disclose the base in the base. There are disclosed a transdermal patch in which the drug concentration is increased and crystals of the drug are precipitated, and a transdermal patch in which the drug is present in a supersaturated state exceeding the saturation solubility in the base.

【0005】しかし、過飽和状態に薬物が存在するよう
な基剤においては、製品の流通段階において薬物結晶が
析出し、薬物の経皮吸収性が低下するという問題があっ
た。
[0005] However, in the case of a base in which a drug is present in a supersaturated state, there is a problem that drug crystals precipitate during the distribution stage of the product, and the transdermal absorbability of the drug is reduced.

【0006】また、薬物結晶を析出させた経皮吸収貼付
剤では、過飽和濃度以上に薬物を含ませる必要があり、
1製剤あたりの薬物量が多くなり、コストが増大すると
いう問題があった。特に特開平4−208229号及び
特開平6−145051号では、感圧接着性高分子系重
合体(具体的にはアクリル系感圧粘着剤)に対する経皮
吸収性薬物の含有量が40重量%以下では局所麻酔剤に
期待される短時間での局所麻酔効果発現を達成すること
が困難であるとし、薬物含有量40〜65重量%に設定
した製剤が開示されている。また、特開平11−496
70号公報には以下のことが記載されている。
In a transdermal patch in which drug crystals are precipitated, the drug must be contained at a supersaturated concentration or higher.
There has been a problem that the amount of drug per preparation increases and the cost increases. Particularly, in JP-A-4-208229 and JP-A-6-145051, the content of the transdermally absorbable drug in the pressure-sensitive adhesive polymer (specifically, acrylic pressure-sensitive adhesive) is 40% by weight. In the following, it is difficult to achieve a local anesthetic effect in a short time, which is expected from a local anesthetic, and a preparation having a drug content of 40 to 65% by weight is disclosed. Also, JP-A-11-496
No. 70 describes the following.

【0007】「最近、貼付用局所麻酔剤として、リドカ
インを60重量%含有するリドカインテープ剤が市販さ
れるに至っている。このリドカインテープ剤は、アクリ
ル系感圧接着剤にリドカインを過飽和に含有させること
により、リドカインの皮膚透過性を確保しており、30
分間の貼付により、静脈留置穿刺時の疼痛緩和が認めら
れるとされている。しかし、臨床の場において、この種
の薬剤は、無痛状態が確実に達成されてはじめて効果が
あると判断されるため、従来のリドカインテープ剤の臨
床現場での使用法としては、患部へ90〜120分間程
度は貼付する必要があるといわれている(臨床麻酔−V
ol.20(2),p.195(1996))。したが
って従来のリドカインテープ剤は投薬管理や患者のコン
プライアンス上の問題があった。」
"Recently, a lidocaine tape preparation containing 60% by weight of lidocaine has been marketed as a local anesthetic for application. This lidocaine tape preparation supersaturates lidocaine in an acrylic pressure-sensitive adhesive. As a result, the skin permeability of lidocaine is ensured,
It is reported that pain after venous indwelling puncture is alleviated by application for a minute. However, in a clinical setting, this kind of drug is judged to be effective only after a painless state is reliably achieved. Therefore, as a conventional method of using a lidocaine tape agent in a clinical setting, 90- It is said that it is necessary to apply for about 120 minutes (Clinical anesthesia-V
ol. 20 (2), p. 195 (1996)). Therefore, the conventional lidocaine tape preparation has problems in medication management and patient compliance. "

【0008】なお、過飽和濃度レベルに達した後に徐々
に薬物結晶を析出させておく経皮吸収貼付剤では、その
析出に要する時間のため製造効率が著しく低下してしま
うという問題があった。また、高濃度の薬物含有および
結晶の存在は粘着力の低下につながり、しかも、高濃度
の薬物適用は、皮膚安全性の面からも望ましくないもの
であった。
In the case of a transdermal patch in which drug crystals are gradually precipitated after reaching a supersaturated concentration level, there is a problem that the production efficiency is significantly reduced due to the time required for the precipitation. In addition, the high concentration of the drug and the presence of crystals lead to a decrease in the adhesive strength, and the application of the high concentration of the drug is also undesirable from the viewpoint of skin safety.

【0009】特開平7−126157号、特開平7−2
15850号あるいは特開平11−49670には、吸
収促進剤としてミリスチン酸イソプロピル、パルミチン
酸イソプロピル、クロタミトンやN−メチル−2−ピロ
リドンといったものを配合することで、薬物の皮膚透過
性を高めるといった技術が開示されている。しかし、こ
れらの吸収促進剤の配合は、一般に薬物の皮膚透過性を
高める一方で、皮膚への刺激性・安全性が問題となって
いる。
JP-A-7-126157 and JP-A-7-2
No. 15850 or JP-A-11-49670 discloses a technique of increasing the skin permeability of a drug by blending an absorption promoter such as isopropyl myristate, isopropyl palmitate, crotamiton or N-methyl-2-pyrrolidone. It has been disclosed. However, incorporation of these absorption enhancers generally raises the skin permeability of the drug, while causing irritation to the skin and safety.

【0010】特開平7−233054号には、ゴム系感
圧粘着剤が皮膚から脂質成分を抽出するために、この脂
質成分が上記感圧粘着剤基剤中に移行し、これに麻酔薬
が溶解して溶解速度が上昇する結果、麻酔薬の皮膚透過
性が高まって十分に高い薬効が速やかに得られるとして
いる。しかし、微量の皮内脂質成分がこのような効果を
もたらすとは言い難い。また、ヒトの皮膚には個人差が
あり、そのためヒトによって、あるいは貼付部位によっ
て皮膚の脂質成分の感圧粘着剤基剤中への移行性が異な
り、その結果麻酔薬の皮膚透過性が大きく変化するとい
う問題があった。さらには、皮膚中の脂質成分が上記感
圧粘着剤基剤中へ移行し、麻酔薬の皮膚透過性が高まる
までに時間がかかるため、麻酔作用の速効性が不十分で
あった。
Japanese Patent Application Laid-Open No. Hei 7-233504 discloses that a rubber-based pressure-sensitive adhesive extracts a lipid component from the skin, and this lipid component is transferred into the pressure-sensitive adhesive base, and an anesthetic is added thereto. It says that as a result of dissolution and an increase in the dissolution rate, the skin permeability of the anesthetic increases, and a sufficiently high drug effect can be obtained quickly. However, it is hard to say that a small amount of intradermal lipid component provides such an effect. In addition, there are individual differences in human skin, and therefore, the migration of lipid components of the skin into the pressure-sensitive adhesive base varies depending on the human or the application site, resulting in a large change in the skin permeability of anesthetics There was a problem of doing. Furthermore, it takes a long time for the lipid components in the skin to migrate into the pressure-sensitive adhesive base and increase the permeability of the anesthetic to the skin, so that the immediate effect of the anesthetic action was insufficient.

【0011】なお、当該公報には基剤として、場合によ
り本発明の膏体の成分構成に含まれるところの粘着付与
剤や流動パラフィンを含ませることができる旨の記載が
あるものの、実施例もなく、流動パラフィンが使用され
たときに発現する優れた局所麻酔効果を示唆する記載は
全くなかった。さらに、その実施例から得られる製剤
は、その組成から粘着性は全く無く、皮膚への固着が困
難であるため薬物の吸収に劣るものである。
[0011] Although the publication discloses that a tackifier and liquid paraffin, which are optionally contained in the component composition of the plaster of the present invention, can be contained as a base, examples are also provided. In addition, there was no description suggesting an excellent local anesthetic effect developed when liquid paraffin was used. Furthermore, the preparations obtained from the examples have no tackiness due to their composition and are difficult to adhere to the skin, so that they have poor drug absorption.

【0012】特開平10−147521号には、本発明
の膏体の構成が一部記載されてはいるが、当該公報に開
示されているのは帯状疱疹あるいは帯状疱疹後神経痛の
持続性の痛みの軽減のために利用でき、該薬効成分を安
定的にかつ長時間にわたって経皮吸収させることができ
る持続性疼痛緩和用貼付剤に関するものであり、本発明
で開示されるような局所麻酔効果の速効性については全
く示唆がなされていなかった。
Japanese Patent Application Laid-Open No. Hei 10-147521 describes a part of the composition of the plaster of the present invention. However, the gazette discloses the persistent pain of herpes zoster or postherpetic neuralgia. The present invention relates to a patch for sustained pain relief which can be used for the reduction of pain, and which can stably and percutaneously absorb the medicinal ingredient over a long period of time, and has a local anesthetic effect as disclosed in the present invention. There was no suggestion of immediate effect.

【0013】また、従来の製剤にあった取扱い性の欠
点、すなわち、製剤が柔らかすぎて、剥離ライナーの除
去の際あるいは貼付の際に、容易に折れ曲がり粘着面同
士が接着してしまい使用不能となることがあった。たと
え接着した粘着面同士を引き剥がしても、粘着面が破壊
されて再使用は困難であった。
[0013] In addition, the drawback of handling properties of the conventional preparations is that the preparations are too soft and easily bend when the release liner is removed or pasted, and the adhesive surfaces adhere to each other, making it unusable. There was something. Even if the adhered adhesive surfaces were peeled off from each other, the adhesive surface was destroyed and reuse was difficult.

【0014】[0014]

【課題が解決しようとする課題】局所麻酔剤を、より少
量または低濃度含有し、皮膚への刺激が少なく、皮膚の
状態に関わらず、安全な局所麻酔剤の皮膚透過性を有
し、かつ、取扱い性に優れた局所麻酔用テープ剤を得る
ことが本発明の目的であり、課題である。
[Problem to be Solved by the Invention] A local anesthetic is contained in a smaller amount or at a lower concentration, the skin is less irritating, and regardless of the condition of the skin, it has a safe skin permeability of the local anesthetic, and It is an object of the present invention to obtain a tape preparation for local anesthesia which is excellent in handleability and is a problem.

【0015】[0015]

【課題を解決するための手段】本発明者らは鋭意研究し
た結果、局所麻酔剤を下記のテープ剤に配合すること
で、より低濃度で安全性が高く、製造効率及び製造コス
トに優れ、取扱い性に優れた局所麻酔用テープ剤が得ら
れることを見出し、本発明を完成した。
Means for Solving the Problems As a result of intensive studies, the present inventors have found that by blending a local anesthetic in the following tape preparation, a lower concentration, higher safety, higher production efficiency and higher production cost, The present inventors have found that a tape preparation for local anesthesia having excellent handleability can be obtained, and completed the present invention.

【0016】本発明の局所麻酔用テープ剤の優れている
点のひとつは、従来のように特別の経皮吸収促進剤を用
いることなく、ゴム系粘着剤組成物からなる膏体の軟化
剤としても用いられ、しかも刺激性がほとんどない流動
パラフィンの、図らずも局所麻酔効果を増強する作用を
見出した点にある。
One of the advantages of the tape for local anesthesia of the present invention is that it can be used as a softening agent for a plaster composed of a rubber-based pressure-sensitive adhesive composition without using a special percutaneous absorption enhancer as in the prior art. Is also used, and has the effect of inadvertently enhancing the local anesthetic effect of liquid paraffin with little irritation.

【0017】本発明の局所麻酔用テープ剤のもうひとつ
の優れている点は、支持体上に膏体を担持させた構成体
が、適度な剛性を有するため、剥離ライナーを除去して
製剤を貼付する際に、自重により折れ曲がって粘着面同
士が接着してしまうことがない点である。さらに、粘着
剤が適度な凝集性を持つために、粘着面同士が接着して
しまっても、容易に引き剥がして再使用が可能である。
Another excellent point of the tape for local anesthesia of the present invention is that the composition in which the plaster is supported on the support has an appropriate rigidity. When sticking, it is a point which does not bend by an own weight and adhesive surfaces adhere. Further, since the pressure-sensitive adhesive has an appropriate cohesive property, even if the pressure-sensitive adhesive surfaces adhere to each other, the pressure-sensitive adhesive can be easily peeled off and reused.

【0018】本発明の局所麻酔用テープ剤は、柔軟な支
持体上に局所麻酔剤5〜30重量%、ゴム系粘着剤10
〜50重量%、粘着付与剤10〜50重量%、流動パラ
フィン10〜50重量%を主な成分として含有した膏体
を担持させ、かつその構成体が適度な剛性を有すること
を特徴としている。
The tape for local anesthesia of the present invention comprises 5 to 30% by weight of a local anesthetic and a rubber-based adhesive 10 on a flexible support.
It is characterized in that it supports a plaster body containing 〜50% by weight, 10-50% by weight of a tackifier and 10-50% by weight of liquid paraffin as main components, and its constituent body has appropriate rigidity.

【0019】本発明の局所麻酔用テープ剤に用いられる
支持体は、高分子化合物例えばポリエチレン、ポリプロ
ピレン、レーヨン、コットンポリエステル、ポリビニル
アルコールなどからなる織布、不織布、シート又はこれ
らにフィルムをラミネートしたものなどが用いられる。
とくに本発明では貼付時の取扱い性を向上させるため、
剥離ライナーを除去した製剤が、少なくとも容易に折れ
曲がって粘着面同士が接着してしまわない程度の剛性が
保たれるような支持体を選択することが必要である。例
えばJIS一般織物試験法における剛軟性としてドレー
プ係数で0.20〜0.65の支持体を用いるのがよ
い。0.20より小さいと、柔らかすぎて剥離ライナー
を除去した製剤が、容易に折れ曲がって粘着面同士が接
着してしまうおそれがあるし、0.65より大きいと皮
膚への追従が悪くなる。また、医療現場において製剤の
貼付及び剥離の有無が容易に確認できるように支持体の
色を例えば白色等の目立ちやすい色にすることが望まし
い。
The support used in the tape preparation for local anesthesia of the present invention may be a woven fabric, nonwoven fabric, sheet made of a high molecular compound such as polyethylene, polypropylene, rayon, cotton polyester, polyvinyl alcohol or the like, or a laminate of these films. Are used.
In particular, in the present invention, in order to improve the handleability at the time of pasting,
It is necessary to select a support that maintains the rigidity of the preparation from which the release liner has been removed, at least so that the preparation does not easily bend and the adhesive surfaces do not adhere to each other. For example, it is preferable to use a support having a drape coefficient of 0.20 to 0.65 as the stiffness in the JIS general textile test method. If it is less than 0.20, the preparation, which is too soft and the release liner is removed, may be easily bent and the adhesive surfaces may adhere to each other. If it is more than 0.65, it may be difficult to follow the skin. In addition, it is desirable that the color of the support be a conspicuous color such as white, for example, so that the presence or absence of sticking and peeling of the preparation can be easily confirmed at the medical site.

【0020】本発明の局所麻酔用テープ剤に用いられる
基剤成分であるゴム系粘着剤としては、例えばスチレン
−イソプレン−スチレンブロック共重合体(SIS)、
ポリイソブチレンポリマー、スチレン−ブタジエンブロ
ックポリマー、ポリブテン、ポリイソプレン、ブチルゴ
ム、天然ゴム等の中から1種または2種類以上用いる。
その使用量は10〜50重量%、好ましくはそれらの合
計が20〜30重量%を用い、少なすぎると凝集力が低
下し、粘着剤の凝集破壊を起こして品質の劣化や糊残り
する等の皮膚汚染の原因となり、また多すぎると硬くな
りすぎて適度な粘着力が得られず、好ましくない。
The rubber-based pressure-sensitive adhesive which is a base component used in the tape for local anesthesia of the present invention includes, for example, styrene-isoprene-styrene block copolymer (SIS),
One or more of polyisobutylene polymer, styrene-butadiene block polymer, polybutene, polyisoprene, butyl rubber, natural rubber and the like are used.
The used amount is 10 to 50% by weight, preferably 20 to 30% by weight in total. If the amount is too small, the cohesive strength is reduced and cohesive failure of the pressure-sensitive adhesive is caused to deteriorate the quality or leave adhesive. It is not preferable because it causes skin contamination, and when it is too much, it becomes too hard and a proper adhesive strength cannot be obtained.

【0021】本発明の局所麻酔用テープ剤に用いられる
粘着付与剤は、粘着基剤と組み合わせることによりはじ
めて粘着性を生み出す樹脂である。この粘着付与成分が
含まれないと、粘着力が発生せず貼付剤としての機能を
果たし得ない。例えば脂環族飽和炭化水素樹脂、テルペ
ン樹脂、ロジン樹脂等の中から1種または2種類以上配
合することができる。配合量は10〜50重量%を用
い、好ましくはそれらの合計が20〜45重量%を用
い、少なすぎると十分な粘着力が得られず、また多すぎ
ると粘着力が大きすぎて角質の剥離を起こす等、皮膚へ
の物理的な刺激となり、好ましくない。
The tackifier used in the tape for local anesthesia of the present invention is a resin that produces tackiness only when combined with an adhesive base. If the tackifier is not contained, no adhesive force is generated and the adhesive cannot function as a patch. For example, one or more kinds of alicyclic saturated hydrocarbon resins, terpene resins, rosin resins and the like can be blended. The compounding amount is 10 to 50% by weight, preferably the total is 20 to 45% by weight. If the amount is too small, a sufficient adhesive force cannot be obtained, and if it is too large, the adhesive force is too large to exfoliate the keratin. It causes physical irritation to the skin, such as causing skin irritation, which is not preferable.

【0022】本発明の局所麻酔用テープ剤の膏体に用い
られる軟化剤として及び局所麻酔剤の放出調節剤として
働く流動パラフィンは、配合量としては通常10〜50
重量%を用い、好ましくは15〜45重量%を用い、少
なすぎると皮膚に対する適度な追従性、接着性及び局所
麻酔剤の放出促進効果が得られず、また多すぎると粘着
剤の凝集破壊を起こし、品質の劣化、糊残り等皮膚の汚
染の原因となり好ましくない。
Liquid paraffin, which acts as a softening agent and as a local anesthetic release modifier used in the plaster of the tape for local anesthesia of the present invention, is usually incorporated in an amount of 10 to 50.
%, Preferably 15 to 45% by weight. If the amount is too small, appropriate follow-up properties to the skin, the adhesion and the effect of promoting the release of the local anesthetic are not obtained. It is not preferable because it causes skin contamination such as waking up, deterioration of quality and adhesive residue.

【0023】本発明に用いられる局所麻酔剤は、通常5
〜30重量%を使用するのが好ましい。これより少ない
と所望の局所麻酔効果が期待できない。また、これより
多くしても局所麻酔剤の結晶が析出しはじめるため、そ
れ以上の薬物の放出特性向上は期待できない。しかも製
剤中の薬物濃度の不必要な増加は、粘着力の低下につな
がるだけでなく、皮膚安全性の面からも望ましくない。
The local anesthetic used in the present invention is usually 5
It is preferred to use 3030% by weight. If it is less than this, a desired local anesthetic effect cannot be expected. Further, even if the amount is more than this, since crystals of the local anesthetic start to precipitate, further improvement in drug release characteristics cannot be expected. Moreover, an unnecessary increase in the drug concentration in the preparation not only leads to a decrease in adhesive strength, but is also undesirable from the viewpoint of skin safety.

【0024】なお、上記膏体組成物においては、膏体の
厚みなどを保持したり、膏体が柔軟になり過ぎ支持体へ
浸透するのを防止するために充てん剤を添加することも
できる。充てん剤としては、例えば、カオリン、酸化チ
タン、タルク、酸化亜鉛、炭酸カルシウム、珪酸塩、珪
酸アルミニウム水和物、硫酸バリウム、硫酸カルシウム
等が挙げられる。
In the above plaster composition, a filler may be added to keep the plaster thickness or the like or to prevent the plaster from becoming too soft and penetrating into the support. Examples of the filler include kaolin, titanium oxide, talc, zinc oxide, calcium carbonate, silicate, aluminum silicate hydrate, barium sulfate, calcium sulfate, and the like.

【0025】また、本発明の膏体組成物中には、必要に
応じ一般の貼付剤に使用されるジブチルヒドロキシトル
エン等の抗酸化剤、ハッカ油等の香料等を添加すること
ができる。
The plaster composition of the present invention may contain an antioxidant such as dibutylhydroxytoluene and a fragrance such as peppermint oil which are used in general patches, if necessary.

【0026】本発明組成物を製造する方法の一例を示す
と、スチレン−イソプレン−スチレンブロック共重合
体、粘着付与剤、流動パラフィン及び必要に応じて添加
する充てん剤及び任意成分の混合物を加熱融解しかく拌
混合する。この液に局所麻酔剤を融解させ、均一にかく
拌混合し、得られた溶液を剥離処理したプラスチックフ
ィルム上に均一に塗布し、デバイスの支持体となる不織
布と貼り合わせ、得られたものを所定の大きさに裁断す
る事により経皮吸収製剤を得る。なお、製造方法は特に
上記方法に限定されるものではなく、配合順序、かく拌
方法及び材料などを変更しても製造可能である。
An example of the method for producing the composition of the present invention is as follows. A mixture of a styrene-isoprene-styrene block copolymer, a tackifier, a liquid paraffin, a filler to be added as required, and an optional component is heated and melted. Stir and mix. The local anesthetic was melted in this solution, mixed uniformly with stirring, the resulting solution was uniformly applied on a plastic film subjected to peeling treatment, and the resulting solution was bonded to a non-woven fabric serving as a support for the device. A percutaneous absorption preparation is obtained by cutting to a predetermined size. In addition, the production method is not particularly limited to the above method, and the production can be carried out even if the mixing order, the stirring method, the materials, and the like are changed.

【0027】[0027]

【作用】従来、静脈留置針穿刺時、硬膜または腰椎また
は関節穿刺時、皮膚小手術前の局所麻酔等に対して満足
な効果を得ようと、薬物の結晶を析出させた経皮吸収貼
付剤や、基剤に対し薬物を過飽和状態で存在させた経皮
吸収貼付剤が検討されていたが、不必要に多い薬物を使
用することによるコストの増大や皮膚安全性の問題、流
通段階での薬物結晶析出による経皮吸収性の低下、ある
いは製造効率の低下といった問題があったのに対し、本
発明の局所麻酔用テープ剤では、より少ない薬物量で所
望の効果を発現し、製造効率、皮膚安全性に優れた製剤
を得ることができる。また、取扱い性においても従来に
ない優れた特性を発揮する。
Conventionally, in order to obtain a satisfactory effect on puncture of a venous indwelling needle, dural or lumbar spine or joint puncture, and local anesthesia before skin minor surgery, percutaneous absorption with drug crystals precipitated. Percutaneous absorption patches in which the drug is present in a supersaturated state with respect to the drug and the base have been studied. In contrast, there were problems such as a decrease in transdermal absorbability due to the precipitation of drug crystals or a decrease in production efficiency, whereas the tape preparation for local anesthesia of the present invention exhibited a desired effect with a smaller amount of drug, and showed an increase in production efficiency. Thus, a preparation having excellent skin safety can be obtained. In addition, it has excellent characteristics that have never been used before.

【0028】[0028]

【実施例】【Example】

【0029】以下に実施例及び比較例並びに試験実施例
を示し本発明を更に説明する。
Hereinafter, the present invention will be further described by showing Examples, Comparative Examples and Test Examples.

【0030】表1に示す処方に基づき、以下の方法によ
り実施例1〜4、比較例1及び特開平7−233054
号記載の実施例に基づいた比較例3(軟化剤、粘着付与
剤等を含まない)のテープ剤を製造した。
Based on the formulations shown in Table 1, the following methods were used to prepare Examples 1 to 4, Comparative Example 1, and JP-A-7-233054.
Comparative Example 3 (not including a softener, a tackifier, etc.) based on the example described in No. 1 was manufactured.

【0031】[0031]

【表1】 [Table 1]

【0032】(実施例1〜4及び比較例1の製造方法)
スチレン−イソプレン−スチレンブロック共重合体、脂
環族飽和炭化水素樹脂、流動パラフィン及び酸化防止剤
を加熱融解、かく拌した後、リドカインを融解し均一に
かく拌混合した。この液を均一に塗布したプラスチック
フィルムを、ポリプロピレン製不織布と貼り合わせ、約
3×5cmの大きさに裁断してテープ剤を製造した。
(Production method of Examples 1 to 4 and Comparative example 1)
The styrene-isoprene-styrene block copolymer, alicyclic saturated hydrocarbon resin, liquid paraffin and antioxidant were heated and melted and stirred, and then lidocaine was melted and uniformly stirred and mixed. A plastic film uniformly coated with this solution was bonded to a polypropylene nonwoven fabric and cut into a size of about 3 × 5 cm to produce a tape.

【0033】(比較例3の製造方法)スチレン−イソプ
レン−スチレンブロック共重合体を加熱融解した後、リ
ドカインを融解し均一にかく拌混合した。この液を実施
例と同様にしてリドカインを10重量%含有するテープ
剤を製造した。
(Production method of Comparative Example 3) After the styrene-isoprene-styrene block copolymer was heated and melted, lidocaine was melted and uniformly stirred and mixed. A tape preparation containing 10% by weight of lidocaine was produced from this solution in the same manner as in the example.

【0034】試験例1(in vitro皮膚透過試
験) 実施例1〜4及び比較例2(市販リドカインテープ剤
(リドカイン60%含有))の5種類を試料とし、下記
の方法でリドカインの皮膚透過性を評価した。試験結果
を図1に示す。
Test Example 1 (In Vitro Skin Permeation Test) Five kinds of Examples 1-4 and Comparative Example 2 (commercially available lidocaine tape (containing 60% lidocaine)) were used as samples, and the skin permeability of lidocaine was determined by the following method. Was evaluated. The test results are shown in FIG.

【0035】(実験方法)水平型拡散セルにヘアレスマ
ウス側腹部皮膚を角質層がドナー側となるように装着
し、各試料をそれぞれドナー側の皮膚表面に貼付した。
レセプター側にレセプター液(生理食塩水)を入れ、3
7℃の温度に保ち、経時的にレセプター液を採取し、ヘ
アレスマウス皮膚を透過したリドカイン量をHPLC法
により測定した。
(Experimental Method) The abdominal skin of a hairless mouse was attached to a horizontal diffusion cell such that the stratum corneum was on the donor side, and each sample was attached to the skin surface on the donor side.
Put the receptor solution (saline) on the receptor side,
While maintaining the temperature at 7 ° C., the receptor solution was collected over time, and the amount of lidocaine permeating the skin of the hairless mouse was measured by the HPLC method.

【0036】その結果、図1に示すように実施例1(リ
ドカイン濃度5%)は比較例2より低い透過性を示した
ものの、実施例2、3及び4は比較例2に匹敵する皮膚
透過性を示した。この結果から、本発明品の実施例2、
3及び4は比較例2と同程度の効果が期待され、特に実
施例2は比較例2のわずか9分の1の薬物濃度におい
て、ほぼ同等の効果が得られるものと思われた。
As a result, as shown in FIG. 1, Example 1 (lidocaine concentration 5%) showed lower permeability than Comparative Example 2, but Examples 2, 3 and 4 showed skin permeability comparable to Comparative Example 2. Showed sex. From these results, Example 2 of the product of the present invention,
3 and 4 were expected to have the same effect as Comparative Example 2, and it was thought that Example 2 could obtain almost the same effect at a drug concentration of only 1/9 of Comparative Example 2.

【0037】試験例2(モルモット背部皮膚における局
所麻酔作用) 実施例3、比較例1及び比較例2を試料とし、下記の方
法でリドカインの局所麻酔効果を評価した。
Test Example 2 (Local anesthetic action on guinea pig back skin) Using Example 3, Comparative Example 1 and Comparative Example 2 as samples, the local anesthetic effect of lidocaine was evaluated by the following method.

【0038】(試験方法)除毛したモルモット背部をマ
ンドリン線で刺激し、明らかな皮膚の収縮反応が起こる
部位に各試料(2.5cm×3cm)を貼付した。30
分後に試料を除去し、除去10分後から除去部位を一ヶ
所あたり5点ずつ、10分ごとにマンドリン線で刺激
し、そのときの皮膚収縮反応回数(Pain scor
e;0〜5)を記録した。
(Test Method) Each sample (2.5 cm × 3 cm) was applied to a site where a dehaired guinea pig was stimulated with a mandolin line and a clear skin contraction reaction occurred. 30
After 10 minutes, the sample was removed, and after 10 minutes from the removal, the removal site was stimulated with a mandolin line at 5 points per location every 10 minutes, and the number of skin contraction reactions (Pain score) at that time was performed.
e; 0-5) were recorded.

【0039】その結果、図2に示すように実施例3の局
所麻酔作用は、薬物濃度が比較例2の6分の1であるに
もかかわらず、これと同程度であった。
As a result, as shown in FIG. 2, the local anesthetic action of Example 3 was almost the same as that of Comparative Example 2 although the drug concentration was 1/6 that of Comparative Example 2.

【0040】試験例3(速効的な表面麻酔作用) 実施例1〜3、比較例2及び比較例3の5種類を試料と
し、下記の方法でリドカインの局所麻酔効果を評価し
た。
Test Example 3 (Efficient Surface Anesthetic Action) Using the five types of Examples 1-3, Comparative Example 2 and Comparative Example 3 as samples, the local anesthetic effect of lidocaine was evaluated by the following method.

【0041】(試験方法)健常成人男子20名を対象と
して検討した。被験者の手甲皮膚をマンドリン線で刺激
し、痛点(痛みの程度:3)を選定後、利き腕とその反
対の手甲皮膚の痛点に実施例3を1枚または比較例2を
1枚につきそれぞれ30分間という短時間貼付した。試
料除去直後に痛点をマンドリン線で刺激し、下記の基準
に従って疼痛の程度を評価した。
(Test Method) The study was conducted on 20 healthy adult males. After stimulating the back skin of the subject with a mandolin line and selecting a pain point (degree of pain: 3), the pain point on the dominant arm and the back skin opposite to the dominant arm is 30 minutes for each of Example 3 or Comparative Example 2 for 30 minutes. For a short time. Immediately after removing the sample, the pain point was stimulated with a mandolin line, and the degree of pain was evaluated according to the following criteria.

【0042】(麻酔効果判定基準) 0:無痛 1:少し痛い 2:痛い 3:すごく痛い(Criteria for judging anesthetic effect) 0: Painless 1: Slightly painful 2: Painful 3: Very painful

【0043】その結果、表2に示すように実施例3には
比較例2とほぼ同等の局所麻酔効果が認められた。ま
た、実施例1及び実施例2についても、若干比較例2よ
り効果は劣るものの、局所麻酔効果は十分発揮されてい
ることがわかった。なお、比較例3については実施例3
よりも効果が劣った。すなわち速効性についても本発明
の局所麻酔用テープ剤が優れていることが確認された。
As a result, as shown in Table 2, the local anesthetic effect of Example 3 was almost equivalent to that of Comparative Example 2. It was also found that the local anesthetic effect was sufficiently exhibited in Examples 1 and 2, though the effect was slightly inferior to Comparative Example 2. In addition, about Comparative Example 3, Example 3
Less effective than That is, it was confirmed that the tape preparation for local anesthesia of the present invention was also excellent in terms of immediate effect.

【0044】[0044]

【表2】 [Table 2]

【0045】試験例4(市販品との使用感テスト) 実施例3及び比較例2を用い、被験者20名における使
用感テストを行った。被験者が具体的な貼付方法の説明
を受けずに、両製剤を失敗せず貼付できるかどうかを調
べた。また、ライナー除去後の製剤について、故意に粘
着面同士を接着し、再び剥離して貼付可能かどうか試験
した。その結果表3に示すように、実施例3については
20名全員が正確に貼付できたのに対し、比較例2は半
分近い9名が失敗した(ライナー除去後の製剤に剛性が
ないために、貼付の際に自重により折れ曲がり、粘着面
同士がくっついてしまった)。また、実施例3は20名
全員が粘着面同士を接着させた後、再剥離及び再貼付が
可能であったが、比較例2については15名の製剤につ
いて膏体の破壊が起こり、再剥離後は貼付できなかっ
た。
Test Example 4 (Usability test with commercially available product) Using Example 3 and Comparative Example 2, a usability test was performed on 20 subjects. It was examined whether or not the subjects could apply both formulations without fail, without being instructed on the specific application method. Further, with respect to the preparation after removal of the liner, it was tested whether the adhesive surfaces were intentionally adhered to each other, peeled off again and applied. As a result, as shown in Table 3, all of the 20 patients were able to correctly adhere to Example 3 whereas 9 of Comparative Example 2 failed (although the formulation after liner removal had no rigidity). , It was bent by its own weight when pasted, and the adhesive surfaces were stuck together.) Further, in Example 3, the re-peeling and re-applying were possible after all the 20 persons adhered the adhesive surfaces to each other. However, in Comparative Example 2, the paste was destroyed for the preparation of 15 persons, and the re-peeling was performed. After that, it could not be pasted.

【0046】[0046]

【表3】 [Table 3]

【0047】試験例5(皮膚安全性試験) 健常成人ボランティア30名(男性24名、女性6名:
平均年齢31.1歳)を対象とし、実施例3を上腕内側
に2時間及び4時間貼付した。なお、白色ワセリンを対
照として用いた。判定は、貼付2時間及び4時間後に製
剤を除去・清払した後、1時間後及び24時間後の2回
行った。判定基準は下記の基準に従って行い、また製剤
の安全性をあらわす基準として須貝に従った評点により
皮膚刺激指数を求めた。
Test Example 5 (Skin safety test) 30 healthy adult volunteers (24 men, 6 women:
Example 3 was applied to the inner side of the upper arm for 2 hours and 4 hours. In addition, white petrolatum was used as a control. The determination was performed twice, 1 hour and 24 hours after the preparation was removed and cleaned 2 hours and 4 hours after application. The criteria were determined according to the following criteria, and the skin irritation index was determined by scoring according to Sugai as a standard indicating the safety of the preparation.

【0048】(判定基準) 判定 評点 − 0 :反応なし ± 0.5 :かるい紅斑 + 1 :紅斑 ++ 2 :紅斑+腫脹 +++ 3 :紅斑+腫脹+丘疹〜小水疱 ++++ 4 :大水疱(Judgment Criteria) Judgment Score -0: No response ± 0.5: Light erythema +1: Erythema ++ 2: Erythema + swelling +++ 3: Erythema + swelling + papules to vesicles +++ 4: Large blister

【0049】(皮膚刺激指数の算出法) 皮膚刺激指数=(除去1時間後及び24時間後で刺激の
強い方の評点合計)÷(試験例数)×100
(Calculation method of skin irritation index) Skin irritation index = (total score of one with strong irritation after 1 hour and 24 hours after removal) / (number of test examples) × 100

【0050】その結果、表4及び表5に示すように、2
時間貼付では除去1時間後に実施例3は30例中1例に
±反応が認められたが、除去24時間後には30例すべ
て反応は認められなかった。また、4時間貼付では除去
1時間後、除去24時間ともに30例すべて反応はなか
った。なお、皮膚刺激指数については、須貝による成人
正常皮膚に適用する製剤としての評価基準において1
5.0未満を安全品としているが、本発明の実施例3は
1.7であり、安全であると判断された。
As a result, as shown in Tables 4 and 5,
In the time affixing, 1 hour after removal, a reaction was observed in 1 out of 30 cases in Example 3, but no reaction was observed in all 30 cases 24 hours after removal. In addition, in the case of sticking for 4 hours, there was no reaction in all 30 cases both 1 hour after removal and 24 hours after removal. The skin irritation index is 1 according to the evaluation criteria for a preparation applied to adult normal skin by Sugai.
Although less than 5.0 was regarded as a safe product, Example 3 of the present invention was 1.7, which was determined to be safe.

【0051】[0051]

【表4】 [Table 4]

【0052】[0052]

【表5】 [Table 5]

【0053】試験例6(静脈留置針穿刺時痛に対する局
所麻酔効果) 静脈留置針穿刺を必要とする20歳〜76歳の治療予定
者60例を対象に、実施例3または比較例2の製剤を3
0分間貼付し、剥離後に静脈留置針を穿刺し、そのとき
の疼痛の程度を問診して、下記の5段階で評価した。
Test Example 6 (Local anesthetic effect on pain at the time of venous indwelling needle puncture) Preparation of Example 3 or Comparative Example 2 for 60 patients to be treated aged 20 to 76 who need venous indwelling needle puncture 3
It was stuck for 0 minutes, punctured with a venous indwelling needle after exfoliation, the degree of pain at that time was asked, and the following five levels were evaluated.

【0054】 0.痛くない 1.少し痛い 2.痛い 3.すごく痛い 4.疼痛度評価不能 1)留置針を穿刺したが失敗(同部位再穿刺不可能) 2)穿刺せず0. It doesn't hurt It hurts a little 2. It hurts Very painful 4. Pain assessment not possible 1) Failure to puncture the indwelling needle (impossible to re-puncture the same site) 2) No puncture

【0055】その結果を表6に示した。実施例3貼付群
は、「痛くない」が5例、「少し痛い」が20例であ
り、「少し痛い」以上が25例(83.3%)であっ
た。比較例2貼付群は、「痛くない」が5例、「少し痛
い」が21例であり、「少し痛い」以上が26例(8
9.7%)あった。「少し痛い」以上についてMann
−WhitneyのU検定を行った結果、両群間に有意
差は認められなかった。また、「痛い」は実施例3で5
例、比較例2で3例であり、「すごく痛い」は両群間と
も認められなかった。
Table 6 shows the results. In the group to which Example 3 was applied, 5 cases were “not painful”, 20 cases were “slightly painful”, and 25 cases (83.3%) were “slightly painful” or more. In the comparative example 2 application group, 5 cases were “not painful”, 21 cases were “slightly painful”, and 26 cases were “slightly painful” or more (8 cases).
9.7%). Mann about "slightly painful" and more
As a result of the -Whitney U test, no significant difference was observed between the two groups. “I hurt” is 5 in Example 3.
Example and Comparative Example 2 were 3 cases, and "very painful" was not recognized between both groups.

【0056】[0056]

【表6】 [Table 6]

【0057】[0057]

【発明の効果】本発明は低濃度で優れた局所麻酔効果を
得ることができた。また、取扱い性に優れ、製造効率、
製造コストにおいても極めて有用な製剤といえるもので
ある。
According to the present invention, an excellent local anesthetic effect can be obtained at a low concentration. In addition, it is excellent in handling, manufacturing efficiency,
It can be said that the preparation is extremely useful in terms of production cost.

【図面の簡単な説明】[Brief description of the drawings]

【図1】実施例1〜4及び比較例2のヘアレスマウス皮
膚透過性を比較した図である。
FIG. 1 is a diagram comparing skin permeability of hairless mice of Examples 1 to 4 and Comparative Example 2.

【図2】実施例3、比較例1及び比較例2のモルモット
背部皮膚における局所麻酔作用を示した図である。
FIG. 2 is a view showing the local anesthetic action on the skin of the guinea pig back in Example 3, Comparative Example 1 and Comparative Example 2.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61K 47/46 A61P 23/02 A61M 35/00 A61J 1/00 370C A61P 23/02 A61M 35/00 Z (72)発明者 古賀 裕美 佐賀県鹿島市大字納富分2596番地1 祐徳 薬品工業株式会社内 Fターム(参考) 4C076 AA74 AA81 BB31 CC01 DD34A EE58A FF68 4C167 AA72 BB13 BB23 CC01 GG08 GG10 GG14 GG16 GG36 HH17 HH30 4C206 AA02 DB15 DB43 GA18 GA31 KA01 MA03 MA05 MA29 MA52 MA83 ZA21 ZA89 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI theme coat ゛ (Reference) A61K 47/46 A61P 23/02 A61M 35/00 A61J 1/00 370C A61P 23/02 A61M 35/00 Z ( 72) Inventor Hiromi Koga 2596 No. 1, Nobomi, Kashima City, Saga Prefecture F-term (reference) 4C076 AA74 AA81 BB31 CC01 DD34A EE58A FF68 4C167 AA72 BB13 BB23 CC01 GG08 GG10 GG30 H206 DB43 GA18 GA31 KA01 MA03 MA05 MA29 MA52 MA83 ZA21 ZA89

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】 柔軟な支持体上に、局所麻酔剤5〜30
重量%、ゴム系粘着剤10〜50重量%、粘着付与剤1
0〜50重量%、流動パラフィン10〜50重量%を主
な成分として含有した膏体を担持させ、かつその構成体
が皮膚への適度な追従性を有し、少なくとも貼付の際に
自重により折れ曲がるなどして膏体同士が接着しない程
度の適度な剛性を有し、皮膚表面における注射の際の痛
みを軽減するために、あるいは静脈留置針または関節穿
刺時の局所麻酔に使用することを特徴とする局所麻酔用
テープ剤
Claims 1. A local anesthetic 5 to 30 on a flexible support.
% By weight, 10 to 50% by weight of rubber-based adhesive, tackifier 1
It carries a plaster containing 0 to 50% by weight and 10 to 50% by weight of liquid paraffin as main components, and its constituents have an appropriate follow-up property to the skin, and bend by its own weight at least when applied. It has an appropriate rigidity such that plasters do not adhere to each other, and is used for reducing pain at the time of injection on the skin surface, or for local anesthesia at the time of venous indwelling needle or joint puncture. Local anesthetic tape
【請求項2】 局所麻酔剤がリドカイン、テトラカイ
ン、プロカインあるいはそれらの塩からなる群から選ば
れた少なくとも1種である請求項第1項記載の局所麻酔
用テープ剤。
2. The local anesthetic tape preparation according to claim 1, wherein the local anesthetic is at least one selected from the group consisting of lidocaine, tetracaine, procaine and salts thereof.
【請求項3】 JIS一般織物試験法における剛軟性と
してドレープ係数で0.20〜0.65の支持体を用い
ることを特徴とする請求項第1項または第2項記載の局
所麻酔用テープ剤。
3. The tape preparation for local anesthesia according to claim 1, wherein a support having a drape coefficient of 0.20 to 0.65 is used as the stiffness in the JIS general textile test method. .
JP2001337251A 2001-11-02 2001-11-02 Local anesthetic tape Pending JP2002193795A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001337251A JP2002193795A (en) 2001-11-02 2001-11-02 Local anesthetic tape

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001337251A JP2002193795A (en) 2001-11-02 2001-11-02 Local anesthetic tape

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP11131635A Division JP2000319168A (en) 1999-05-12 1999-05-12 Local anesthetic tape preparation

Publications (1)

Publication Number Publication Date
JP2002193795A true JP2002193795A (en) 2002-07-10

Family

ID=19151923

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001337251A Pending JP2002193795A (en) 2001-11-02 2001-11-02 Local anesthetic tape

Country Status (1)

Country Link
JP (1) JP2002193795A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2845598A1 (en) * 2002-10-09 2004-04-16 Philippe Taupin Medical patch used for needle injections and which can be removed without discomfort comprises an anaesthetizing support part that can be separated from a fastening part prior to needle injection
WO2009060629A1 (en) 2007-11-11 2009-05-14 Medrx Co., Ltd. Lidocaine tape preparation
CN110038130A (en) * 2018-01-17 2019-07-23 张洁 Pharmaceutical composition, patch and preparation method thereof, application

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01299215A (en) * 1988-03-01 1989-12-04 Alza Corp Medical device for anesthesis and antibacterial treatment of skin
JPH03161432A (en) * 1989-11-20 1991-07-11 Lion Corp Cataplasm
JPH08225448A (en) * 1995-02-23 1996-09-03 Sekisui Chem Co Ltd Percutaneously absorptive tape for local anesthetization
JPH10147521A (en) * 1996-09-18 1998-06-02 Yuutoku Yakuhin Kogyo Kk Persistent cataplasm for reducing pain
JP2000178186A (en) * 1998-10-05 2000-06-27 Yuutoku Yakuhin Kogyo Kk Percutaneous absorption tape preparation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01299215A (en) * 1988-03-01 1989-12-04 Alza Corp Medical device for anesthesis and antibacterial treatment of skin
JPH03161432A (en) * 1989-11-20 1991-07-11 Lion Corp Cataplasm
JPH08225448A (en) * 1995-02-23 1996-09-03 Sekisui Chem Co Ltd Percutaneously absorptive tape for local anesthetization
JPH10147521A (en) * 1996-09-18 1998-06-02 Yuutoku Yakuhin Kogyo Kk Persistent cataplasm for reducing pain
JP2000178186A (en) * 1998-10-05 2000-06-27 Yuutoku Yakuhin Kogyo Kk Percutaneous absorption tape preparation

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2845598A1 (en) * 2002-10-09 2004-04-16 Philippe Taupin Medical patch used for needle injections and which can be removed without discomfort comprises an anaesthetizing support part that can be separated from a fastening part prior to needle injection
WO2004032907A1 (en) * 2002-10-09 2004-04-22 Philippe Taupin Painlessly removable transdermal medical patch
WO2009060629A1 (en) 2007-11-11 2009-05-14 Medrx Co., Ltd. Lidocaine tape preparation
CN110038130A (en) * 2018-01-17 2019-07-23 张洁 Pharmaceutical composition, patch and preparation method thereof, application
WO2019141178A1 (en) * 2018-01-17 2019-07-25 张洁 Pharmaceutical composition, patch and manufacturing method thereof, analgesic method, and application

Similar Documents

Publication Publication Date Title
JP3930984B2 (en) Transdermal preparation
US20180110739A1 (en) Transdermal Delivery Systems
WO2004100959A1 (en) External patch containing estrogen and/or progestogen
JP2006241179A (en) Adhesive and patch preparation
KR102363218B1 (en) Rotigotine-containing patch
JP3159688B2 (en) Transdermal absorption tape
KR20060086319A (en) Tape preparation
JPH10147521A (en) Persistent cataplasm for reducing pain
EP2934403B1 (en) Patch for treatment of eyelid diseases containing clobetasol
WO2000019986A1 (en) Tape material for transcutaneous absorption
JPH07215850A (en) Percutaneous absorption tape for local anestasia
JP2002193795A (en) Local anesthetic tape
JPH11222443A (en) Percutaneous absorption-promoting composition and percutaneous absorption preparation
JP4468669B2 (en) Hypoallergenic patch
JP2000319168A (en) Local anesthetic tape preparation
JPH1149670A (en) Percutaneously absorbable preparation for local anesthesia
JPH09291028A (en) Plaster
JPH06199660A (en) Patch and its production
JPH08310946A (en) Percutaneous absorbable pharmaceutical preparation
JP4167750B2 (en) Transdermal absorption base and percutaneous absorption preparation containing the base
JPH07215847A (en) Tape for sleepiness prevention
JPH0616542A (en) Medical adhesive tape or sheet
JP3525272B2 (en) Skin sticking sheet
JP4658299B2 (en) Transdermal patch for external use
JPWO2009096354A1 (en) Fentanyl-containing external patch

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091013

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100309